Grifols, S.A. Avinguda de la Generalitat 152 - 158 08174 Sant Cugat del Vallès Barcelona - ESPAÑA Tel. [34] 935 710 500 Fax [34] 935 710 267 www.grifols.com P ursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following : OTHER RELEVANT INFORMATION In the cont ext of considerable g eopolitical uncertainty and market volatility , the Board of Directors of Grifols, S.A communicates the following: - Grifols advance s firmly in the execution of a strategic growth plan which continues to create sustainable value for all its shareholders. The company’s fundamentals remain solid and robust . - The development of key Biotest innovation projects continues advancing and , assuming the two new protein products IgM and fibrinogen receive regulatory approval and are fully rolled out into the market, these products are expected to contribute significantly to Grifols’ operating profit. These projects complement Grifols’ current innovation projects and contribute to the company’s soli d product development pipeline . - The volume of plasma collection has rebounded from pandemic lows . S ince May 2022 , monthly plasma collection volume s have been exceeding the average monthly collection volume in 2019 . The company is also actively working on operating cost reductions , as well as continuous improvement in operational efficiencies while re building inventory . Increased plasma collection has in turn driven r evenue growth; the company forecasts revenues for the second half of 2022 to be up by a double digit percentage amount compared to the second half of 2021. - The strategic agreement to increase self - sufficie ncy in Canada strengthens Grifols’ positioning as partner of choice in a pioneering public - private collaboration model in the industry , which together with that of Egypt, could be replicated in other countries. - The re organization of the company ’s organizational structure and operational processes , to accelerate greater agility and focus on the business units, has already been implemented. - At the same time, Grifols continues to attract highly qualified talent , with two new execut ives with recognized international careers expected to join the company to manage the Biopharma and Plasma Procurement business units. Further detail will be provided shortly . - We reiterate this Board’s commitment to reduce debt levels . The B oard is evaluating several strategic alternatives to achieve that goal while also improv ing the company’s cash flow profile . The B oard also notes that the company had cash and unrestricted revolver borrowing capacity totaling over EUR 1.3 billion as of August 31, 2022. In all its endeavors, the B oard is keenly focused on increasing value for all shareholders.

- Grifols plans to continue to enhance the frequency and effectiveness of Grifols’ communications. We would like also to announce th at commencing with the first quarter of 2023, Grifols will publish quarterly earnings reports. In Barcelona , on September 25, 2022 President of the Board of Directors Lead Independent Director Víctor Grífols Roura Carina Szpilka Legal Disclaimer. This communication contains forward - looking information and statements about Grifols based on current assumptions and forecasts made by Grifols management, including statements regarding plans, objectives and expectations with respect to products, operating efficiencies, debt levels, strategy and management , and statements regarding future performance. Forward - looking statements are statements th at are not historical facts and are generally identified by the word “expected” and similar expressions. Although Grifols believes that the expectations reflected in such forward - looking statements are reasonable, various known and unknown risks, uncertain ties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and/or its products, and the expectations set forth in this communication. These factors include tho se discussed in our public reports filed with the Comision Nacional del Mercado de Valores and the Securities and Exchange Commission, which are accessible to the public. The company assumes no liability whatsoever to update these forward - looking statement s or conform them to future events of developments. Forward - looking statements are not guarantees of future performance.